187 related articles for article (PubMed ID: 17394699)
1. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Neuhouser ML; Till C; Kristal A; Goodman P; Hoque A; Platz EA; Hsing AW; Albanes D; Parnes HL; Pollak M
Cancer Prev Res (Phila); 2010 Mar; 3(3):279-89. PubMed ID: 20179296
[TBL] [Abstract][Full Text] [Related]
2. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer.
Reed SD; Scales CD; Stewart SB; Sun J; Moul JW; Schulman KA; Xu J
J Urol; 2011 Mar; 185(3):841-7. PubMed ID: 21239023
[TBL] [Abstract][Full Text] [Related]
3. Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.
Lü J; Zhang J; Jiang C; Deng Y; Özten N; Bosland MC
Nutr Cancer; 2016; 68(1):1-17. PubMed ID: 26595411
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).
Gritz ER; Arnold KB; Moinpour CM; Burton-Chase AM; Tangen CM; Probstfield JF; See WA; Lieber MM; Caggiano V; Moody-Thomas S; Szczepanek C; Ryan A; Carlin S; Hill S; Goodman PJ; Padberg RM; Minasian LM; Meyskens FL; Thompson IM
Cancer Epidemiol Biomarkers Prev; 2014 Aug; 23(8):1638-48. PubMed ID: 25028457
[TBL] [Abstract][Full Text] [Related]
5. The potential for prostate cancer chemoprevention.
Brawley OW
Rev Urol; 2002; 4 Suppl 5(Suppl 5):S11-7. PubMed ID: 16986061
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review and Pooled Analysis of Hypothesized versus Observed Effect Sizes in Early Phase Cancer Prevention Clinical Trials.
Eickhoff J; Zaborek J; Chen G; Sahasrabuddhe VV; Ford LG; Szabo E; Kim K
Cancer Prev Res (Phila); 2023 Aug; 16(8):471-478. PubMed ID: 37258421
[TBL] [Abstract][Full Text] [Related]
7. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Garnick MB
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091399
[No Abstract] [Full Text] [Related]
8. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Stapff MP; Palm S
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091398
[No Abstract] [Full Text] [Related]
9. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply.
Goodman PJ; Tangen CM; Thompson IM
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091400
[No Abstract] [Full Text] [Related]
10. Case-only trees and random forests for exploring genotype-specific treatment effects in randomized clinical trials with dichotomous endpoints.
Dai JY; LeBlanc M
J R Stat Soc Ser C Appl Stat; 2019 Nov; 68(5):1371-1391. PubMed ID: 32489221
[TBL] [Abstract][Full Text] [Related]
11. Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention.
Klein EA
Rev Urol; 2002; 4 Suppl 5(Suppl 5):S18-28. PubMed ID: 16986062
[TBL] [Abstract][Full Text] [Related]
12. Complementary medicine, chemoprevention, and staging of prostate cancer.
Crawford ED
Rev Urol; 2003; 5 Suppl 6(Suppl 6):S23-32. PubMed ID: 16985973
[TBL] [Abstract][Full Text] [Related]
13. Finasteride and prostate cancer.
Khan MA; Partin AW
Rev Urol; 2004; 6(2):97-8. PubMed ID: 16985587
[No Abstract] [Full Text] [Related]
14. A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.
Maximov PY; Abderrahman B; Curpan RF; Hawsawi YM; Fan P; Jordan VC
Endocr Relat Cancer; 2018 Feb; 25(2):R83-R113. PubMed ID: 29162647
[TBL] [Abstract][Full Text] [Related]
15. Modulatory effects of Crataeva nurvala bark against testosterone and N-methyl-N-nitrosourea-induced oxidative damage in prostate of male albino rats.
Kumar DG; Deepa P; Rathi MA; Meenakshi P; Gopalakrishnan VK
Pharmacogn Mag; 2012 Oct; 8(32):285-91. PubMed ID: 24082632
[TBL] [Abstract][Full Text] [Related]
16. Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells.
Zhao R; Xiang N; Domann FE; Zhong W
Nutr Cancer; 2009; 61(3):397-407. PubMed ID: 19373614
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of prostate cancer: what can be recommended to patients?
Colli JL; Amling CL
Curr Urol Rep; 2009 May; 10(3):165-71. PubMed ID: 19371472
[TBL] [Abstract][Full Text] [Related]
18. A review of phase III clinical trials of prostate cancer chemoprevention.
Thorpe JF; Jain S; Marczylo TH; Gescher AJ; Steward WP; Mellon JK
Ann R Coll Surg Engl; 2007 Apr; 89(3):207-11. PubMed ID: 17394699
[TBL] [Abstract][Full Text] [Related]
19. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
